Irene Orlow, MS & PhD

Attending Biologist & Laboratory Member

Share
Print
Share
Print
Irene Orlow, Attending Biologist & Laboratory Member

Office Phone

212-639-3072

Office Fax

212-717-3666

Education

University of Buenos Aires

Current Research Interests/Research Goals

Dr. Orlow directs the Molecular Epidemiology Laboratory. Her research interests include the study of individual (host) and tumor (somatic) genetics, phenotypic characteristics, and exposures that modulate cancer prognosis in patients with melanoma, breast, lung, and other. She is an active member of the international Genes, Environment, and Melanoma (GEM) Study group since the year 2000, as well as the international InterMEL consortium since 2017.  Studies within GEM include research on the vitamin D receptor gene variants in presence or absence of sun exposure, and chemokine/chemokine receptor variants, and their role as modifiers survival.  Dr. Orlow collaborates with members of the Dermatology Service to evaluate the effect of genetics, phenotypic characteristics, and exposures to further the knowledge of the biology and epidemiology of nevi —a known risk factor for melanoma. She is also evaluating the utility of a novel minimally-invasive technique to help diagnose early stage melanoma from other less fatal skin cancers and banal skin lesions.
Dr. Orlow collaborates with colleagues from other Departments at MSK in one other area of great interest to her, with the goal of understanding the underlying biology responsible for, and potential risk predictors for changes in cognition, and of sleep patterns, in cancer survivors.
Her lab supports additional multidisciplinary investigations, and houses biosample collections for large epidemiologic studies including, among others GEM, InterMEL, WECARE, the National Colonoscopy Study, EDGE, and CASH.

 

Publications

Selected peer-reviewed publications:

  1. Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Evaluation of the clonal origin of multiple primary melanomas using molecular profiling. J Invest Dermatol, 129(8):1972-1982, 2009. PMC2745834
  2. Cotignola J, Chou JF, Roy P, Mitra N, Busam K, Halpern AC, and Orlow I. Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma. J Invest Dermatol 132:1471-1478, 2012. PMID:22336942
  3. Correa DD, Satagopan J, Baser RE, Cheung K, Richards E, Lin M, Karimi S, Lyo J, DeAngelis LM, Orlow I. Apolipoprotein E polymorphisms and cognitive functions in patients with brain tumors. Neurology 83:320-327, 2014. PMC4115606
  4. Gibbs DC, Orlow I, Bramson JI, Kanetsky PA, Luo L, Kricker A, Armstrong BK, Anton-Culver H, Gruber SB, Marrett LD, Gallagher RP, Zanetti R, Rosso S, Dwyer T, Sharma A, La Pilla E, From L, Busam KJ, Cust AE, Ollila DW, Begg CB, Berwick M, Thomas NE; GEM Study Group. Association of Interferon Regulatory Factor-4polymorphism rs12203592 with divergent melanoma pathways. J Natl Cancer Inst.108(7) 1-9, 2016. PMC4948568
  5. Orlow I, Reiner AS, Thomas NE, Roy P, Kanetsky PA, Luo L, Paine S, Armstrong BK, Kricker A, Marrett LD, Rosso S, Zanetti R, Gruber SB, Anton-Culver H, Gallagher RP, Dwyer T, Busam K, Begg CB, Berwick M; GEM Study Group. Vitamin D receptor polymorphisms and survival in patients with cutaneous melanoma: a population-based study. Carcinogenesis. 37(1):30-8, 2016. PMC4715233

View a full listing of Irene Orlow’s journal articles.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Irene Orlow discloses the following relationships and financial interests:

No disclosures meeting criteria for time period


The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at ecoi@mskcc.org.


View all disclosures